Wells Fargo analyst Derek Archila downgraded Apellis Pharmaceuticals to Equal Weight from Overweight with a $58 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
- Apellis submits MAA to EMA for pegcetacoplan for geographic atrophy
- Billionaire Israel Englander Snaps Up These 3 “Strong Buy” Stocks
- Cantor Fitzgerald pharma/biotech analysts hold a dinner